Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +47.16%
#3 Pons Pons +28.18%
#4 Non-Playable Coin Non-Playable Coin +22.05%
#5 OriginTrail OriginTrail +20.43%
#6 龙虾 (Lobster) 龙虾 (Lobster) +19.81%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +19.68%
#8 ApeX ApeX +18.60%
#9 Zora Zora +18.30%
#10 Morpho Morpho +17.03%
Coin of the day
Smilek to the Bank Smilek to the Bank
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Polaryx Therapeutics, Inc. Common Stock Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. Common Stock

PLYX
Classificação em ações #21586
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to... Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Preço da ação
$2.10
Última sincronização: 2026-08-21
Valor de mercado
$104.43M
Variação (1 dia)
-2.10%
Variação (1 ano)
-
País
US
Negociar Polaryx Therapeutics, Inc. Common Stock (PLYX)

Categoria

Healthcare
Lucros da Polaryx Therapeutics, Inc. Common Stock (PLYX)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Polaryx Therapeutics, Inc. Common Stock, os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Polaryx Therapeutics, Inc. Common Stock de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH